Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Express Co (AXP) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance

American Express CoTrade
Charles River Laboratories Intl. IncTrade

Price performance (Past 24H)

Key statistics

American Express Co vs Charles River Laboratories Intl. Inc — how do they compare? American Express Co trades at $355.05 (market cap $242.27B), while Charles River Laboratories Intl. Inc trades at $227.69 (market cap $11.14B). The key difference: American Express Co is far larger — about 21.7× Charles River Laboratories Intl. Inc's market cap, and American Express Co pays a 1.07% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.

AXPCRL
Market Cap
$242.27B$11.14B
Sector
FinancialsHealth
52-Week High
$384.82$233.60
52-Week Low
$292.27$145.57
Dividend Yield
1.07%
Enterprise Value
$14.00B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Express Co

AXP trades at $354.43, up 1.1% today, with a bullish technical signal from moving averages and support at $352. The company reported strong Q1 2026 earnings of $4.28 per share, beating estimates, with revenue reaching $72.23 billion in 2025. Recent news highlights AI investments and a new headquarters, while analyst consensus is a $373.62 price target with 40% buy ratings.

Outlook remains positive driven by revenue growth and premium cardholder expansion, but risks include economic sensitivity and rising debt levels. The stock offers potential upside to consensus targets, supported by institutional confidence and operational momentum, though investors should monitor spending trends and interest rate impacts.

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.

Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American Express Co

American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.

Read more on AXP

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL